Page 1

Q1 Interim Report First quarter of 2021 Summary of financial performance Net sales for the quarter totaled SEK 172 thousand ( 4,438 ) . Sales for the quarter comprised revenue related to Dosell sales . In previous years , this item also included revenue attributable to the Security business area , which has been sold . ● Operating income for the quarter totaled SEK -7,219 thousand ( -5,139 ) . ● Income after financial items for the quarter was SEK -8,891 thousand ( -5,459 ) . Cash flow for the period was SEK 10,789 thousand ( -7,467 ) . Earnings per share for the quarter , basic and diluted , were SEK -0.3 ( -0.2 ) . Equity per share at the end of the period was SEK 0.6 ( 1.0 ) . The equity ratio at the end of the period was 52.2 percent ( 58.4 ) . During the quarter , the company secured ongoing access to working capital through the agreement of a credit facility corresponding to SEK 14 million . Important events in the quarter As a result of iZafe Group's successful pilot projects in 2020 together with partners , pre - orders were received for 450 Dosell 2.0 medication - dispensing robots . The 2.0 model was developed in the first quarter and is starting to be produced in the second quarter with ongoing deliveries . iZafe Group's Italian partner has begun active marketing and negotiations with a large number of pharmacies in northern Italy . In addition , equipment About iZafe Group iZafe Group is a life sciences company conducting research , development and marketing of digital medical solutions and services for safer medication management at home . The company is leading the development of digital dispensing of medication through its medication - dispensing robot Dosell , which reduces the risk of medication errors at home , relieves the burden on healthcare systems , improves quality of life for patients and creates a safer environment for family . ¡ Zafe's customers comprise both consumers and public and private sector care providers in Sweden , the Nordic region and worldwide . iZafe Group primarily sells through well - established partners that already have close , long - term customer relationships with prioritized customer groups . The Group is headquartered in Stockholm , Sweden . iZafe Group AB has been listed on Nasdaq First North Premier Growth Market since 2018 . that packages medication in sachets has been installed at a number of pharmacies . The pilot project with care service provider Attendo has been completed with good results . A phase of developing Dosell is now underway in close dialogue with Attendo to reach more users in the long term . The pilot project with care service provider TioHundra has been completed , with promising potential for the future . Overall , the Dosell medication - dispensing robot has been assessed to be a good solution for supporting day - to - day work at TioHundra . iZafe Group has conducted a test period with potential Dosell users in order to start supplying a consumer version of the service from spring 2021 . Important events since the end of the quarter ¡ Zafe Group issued 1,000,000 share warrants ( T09 ) in connection with the agreement of a credit facility in April 2020. All share warrants were subscribed for , raising SEK 2.6 million for the iZafe Group before issue expenses . ¡ Zafe Group has decided to expand the distribution of information to shareholders and other stakeholders to supplement the communication of important events and regulatory news in line with applicable regulations . The distribution of information is being expanded via the iZafe website for continual updates that are not subject to disclosure rules . In January 2021 , iZafe Group raised just over SEK 4 million through the exercise of series TO 8 B share warrants from the rights issue carried out in 2019 . The CEO and Board exercised all their share warrants . iZafe iZafe Group AB ( publ . ) Corporate ID number : 556762-3391 www.izafe.se | info@izafe.se | +46 ( 0 ) 8-21 11 21